Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Differences in synovial fluid levels of matrix metalloproteinases suggest separate mechanisms of pathogenesis in Lyme arthritis before and after antibiotic treatment.

Lin B, Kidder JM, Noring R, Steere AC, Klempner MS, Hu LT.

J Infect Dis. 2001 Jul 15;184(2):174-80. Epub 2001 Jun 25.

PMID:
11424014
2.

Host metalloproteinases in Lyme arthritis.

Hu LT, Eskildsen MA, Masgala C, Steere AC, Arner EC, Pratta MA, Grodzinsky AJ, Loening A, Perides G.

Arthritis Rheum. 2001 Jun;44(6):1401-10.

5.

Induction of host matrix metalloproteinases by Borrelia burgdorferi differs in human and murine lyme arthritis.

Behera AK, Hildebrand E, Scagliotti J, Steere AC, Hu LT.

Infect Immun. 2005 Jan;73(1):126-34.

7.

Levels of tissue inhibitor of metalloproteinases-1 and matrix metalloproteinases-1 and -8 in gingival crevicular fluid following treatment with enamel matrix derivative (EMDOGAIN).

Okuda K, Miyazaki A, Momose M, Murata M, Nomura T, Kubota T, Wolff LF, Yoshie H.

J Periodontal Res. 2001 Oct;36(5):309-16.

PMID:
11585118
9.

Lyme arthritis in children and adolescents: outcome 12 months after initiation of antibiotic therapy.

Bentas W, Karch H, Huppertz HI.

J Rheumatol. 2000 Aug;27(8):2025-30.

PMID:
10955347
11.
12.
13.

Borrelia burgdorferi induces matrix metalloproteinases by neural cultures.

Perides G, Tanner-Brown LM, Eskildsen MA, Klempner MS.

J Neurosci Res. 1999 Dec 15;58(6):779-90.

PMID:
10583909
14.

Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10.

Tolboom TC, Pieterman E, van der Laan WH, Toes RE, Huidekoper AL, Nelissen RG, Breedveld FC, Huizinga TW.

Ann Rheum Dis. 2002 Nov;61(11):975-80.

15.

Differential expression of matrix metalloproteinases and cyclooxygenases in synovial cells exposed to Borrelia burgdorferi.

Singh SK, Morbach H, Nanki T, Faber C, Baar V, Girschick HJ.

Inflamm Res. 2004 Dec;53(12):689-96.

PMID:
15654517
16.

Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.

Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L, Ulfgren AK.

Rheumatology (Oxford). 2002 May;41(5):484-9.

PMID:
12011369
17.
20.

[Dynamics of matrix metalloproteinase (MMP)-13 in the patients with rheumatoid arthritis].

Itoh T, Uzuki M, Shimamura T, Sawai T.

Ryumachi. 2002 Feb;42(1):60-9. Japanese.

PMID:
11925908

Supplemental Content

Support Center